This morning we watched Moderna rise 6.8% to a price of $36.39 per share. The Large-Cap Biotechnology company is now trading -46.49% below its average target price of $68.01. Analysts have set target prices ranging from $27.0 to $212.0 per share for Moderna, and have given the stock an average rating of hold.
Moderna has an elevated short interest of 12.9%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 4.82. The company's insiders own 9.52% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. 71.6% of Moderna shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in Moderna
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Baillie Gifford and Company | 11% | 42,458,083 | $1,545,049,614 |
| 2024-09-30 | Vanguard Group Inc | 10% | 40,226,214 | $1,463,831,902 |
| 2024-09-30 | Blackrock Inc. | 6% | 25,032,013 | $910,914,937 |
| 2024-09-30 | FMR, LLC | 5% | 17,382,165 | $632,536,973 |
| 2024-09-30 | State Street Corporation | 4% | 16,847,212 | $613,070,034 |
| 2024-09-30 | Theleme Partners LLP | 2% | 7,226,861 | $262,985,467 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 7,069,580 | $257,262,011 |
| 2024-09-30 | Wellington Management Group, LLP | 1% | 5,224,685 | $190,126,283 |
| 2024-09-30 | Flagship Pioneering Inc. | 1% | 4,632,149 | $168,563,899 |
| 2024-09-30 | Invesco Ltd. | 1% | 4,026,604 | $146,528,117 |
For these reasons, we consider that the Moderna is the subject of mixed market sentiment.
